SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is experiencing heightened volatility and intense community debate as traders weigh the potential for a breakout against ongoing frustration over price stagnation. Sentiment remains sharply divided between investors betting on a long-term utility-driven surge and critics who view the asset's current performance as a manipulated, speculative trap.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining significant momentum and trending as investors react to the completed acquisition of Astria Therapeutics and prepare for upcoming data presentations at the AAAAI annual meeting. The community is actively discussing the stock's potential valuation floor, ongoing high short interest, and the disruptive potential of the navenibart pipeline program to trigger a reversal in the long-term price trend.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is trending following a significant surge driven by the release of positive Phase 1 expansion data for its colorectal cancer candidate, Varsetatug Masetecan. The community is actively discussing the stock's massive long-term gains, while debates persist over whether this movement is a sustainable breakout fueled by potential buyout interest or a speculative pump-and-dump scenario.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing increased momentum as investors track the upcoming May 31 PDUFA date for its ADHD treatment, CTx-1301, while closely monitoring for news on a potential U.S. patent allowance. The community is heavily focused on the company's low share float and recent strategic financing, leading to strong sentiment regarding its potential for volatility and significant upside as commercialization milestones approach.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is currently a focal point of intense community debate, with bulls tracking potential supply reduction rumors and long-term accumulation strategies, while bears express skepticism regarding its historical performance and long-term viability. The conversation remains highly polarized, centered on whether the asset will experience a renewed rally or continue to struggle within the broader meme coin market.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

Mistery ($MERY) is trending as a leading native meme coin on the Cronos blockchain, drawing investor attention due to its strong correlation with $CRO and community enthusiasm regarding its perceived 'rug-proof' nature driven by exchange-level ownership. Traders are actively comparing its growth potential to historical meme coin breakouts, with many interpreting current activity as a setup for a sustained bull run.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently under significant pressure following an earnings report that missed revenue expectations and highlighted ongoing bottom-line struggles, fueling intense debate between retail investors who are buying the dip and skeptics concerned about high debt levels and management's performance. The community remains heavily focused on the status of a potential strategic partnership with POSCO and the impact of steel tariffs on the companys long-term recovery.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is seeing high volatility as investors closely monitor for the anticipated announcement of a major hyperscaler tenant for its data center project. While social media sentiment remains divided between hopeful bulls expecting significant upside upon a contract filing and vocal skeptics concerned about project timelines and recent share registration activity, the community is actively tracking industrial progress and energy infrastructure developments as key indicators for a potential breakout.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a significant surge in trading volume and bullish sentiment as investors speculate on potential news or partnership announcements during the upcoming OFC conference. The community is actively debating the company's competitive position in the AI infrastructure and optical interconnect sector, with many focused on the potential for the firm's interposer platform to capture share in the data center market.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is currently trending as investors weigh a significant quarterly earnings miss and substantial restructuring charges against an optimistic 2026 outlook and positive guidance. The community is intensely debating the company's long-term EV pivot, the impact of recent tariff headwinds, and whether management's push for increased profitability justifies the current share price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cassava Sciences (NASDAQ:SAVA) Posts Earnings Results, Beats Estimates By $0.04 EPS

Cassava Sciences (NASDAQ:SAVA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus...

Investors Purchase Large Volume of Cassava Sciences Call Options (NASDAQ:SAVA)

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 12,849 call options on the stock. This is an...

Cassava Sciences (NASDAQ:SAVA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised shares of Cassava Sciences from a "sell" rating to a "hold" rating in a research note on Sunday...

Cassava Sciences (SAVA) Expected to Announce Quarterly Earnings on Tuesday

Cassava Sciences (NASDAQ:SAVA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 3. (View Earnings Report at...

Cassava Sciences (NASDAQ:SAVA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Cassava Sciences from a "hold" rating to a "sell" rating in a report on Saturday...

<ul class="summary-bullets"><li>The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;</li><li>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.</li><li>Cassava previously reached a settlement with the SEC regarding the allegations and paid a monetary penalty without admitting or denying the SEC’s allegations.</li></ul>&nbsp;Cassava Sciences, Inc. (SAVA) said on Thursday that the U.S. Department of Justice has closed its probe into the company over allegations of research misconduct pertaining to its drug Simufilam.The company cooperated wholly with the DOJ’s probe, Cassava said. &nbsp;“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” &nbsp;CEO Richard J. Barry said.Shares of the company traded 2% lower at the time of writing.<h2 class="st-heading-2">Settlement With SEC</h2>Previously in Sept. 2024, Cassava reached a settlement with the U.S. Securities and Exchange Commission (SEC) regarding the allegations and paid a monetary penalty without admitting or denying the claims. &nbsp;The SEC charged Cassava and two former executives — founder and former CEO Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns — with making misleading statements in 2020 regarding the results of a clinical trial for their experimental Alzheimer's treatment, Simufilam.The regulator alleged that the company claimed the drug "significantly improved patient cognition," while failing to disclose that full patient data showed "no measurable cognitive improvement" in episodic memory.Hoau-Yan Wang, a professor at the City University of New York Medical School, who worked with Cassava to develop the drug, was also charged with manipulating trial data.<h2 class="st-heading-2">Simufilam Now</h2>Cassava Sciences is now developing Simufilam to treat tuberous sclerosis complex (TSC)-related epilepsy after dropping its development for Alzheimer’s in early 2025.The decision to discontinue the Alzheimer’s program followed the drug’s failure to show clinical benefit in a late-stage trial.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume improved from ‘low’ to ‘normal’ levels.A Stocktwits user expressed doubts regarding the allegations raised against the company and said they will not invest in it again.<stembedurl>https://www.stocktwits.com/2bitinvestor/message/645330236</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/btm-stock-falls-reverse-split/cZRkTKdR4D4">BTM Stock Pares Early Losses After Company Announces 1-For-7 Reverse Stock Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration a Cassava Sciences, Inc. logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Cassava Sciences Says DOJ Has Closed Probe Into Allegations Around Its Alzheimer’s Program

The probes into the company by both the DOJ and the SEC have now been closed. 

Equity

Cassava Sciences (NASDAQ:SAVA) Upgraded to Hold at Wall Street Zen

Wall Street Zen raised Cassava Sciences from a "sell" rating to a "hold" rating in a report on Sunday...

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO...

Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9% - What's Next?

Cassava Sciences (NASDAQ:SAVA) Trading Down 23.9% - Here's What Happened...

<ul class="summary-bullets"><li>Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency.</li><li>The company added that it no longer expects to initiate the trial in question in the first half of 2026.&nbsp;</li><li>Cassava discontinued Simufilam’s study in mild-to-moderate Alzheimer’s disease in March.</li></ul> Shares of Cassava Sciences, Inc.’s slid a deep 24% on Friday after the U.S. Food and Drug Administration placed a full clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy.The stock is now on track for its worst day in about 9 months.The company was informed by the FDA of the hold in a letter earlier this week, it said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069530/000143774925038313/sava20251218_8k.htm">filing</a> with the Securities and Exchanges Commission. The company now has to provide the agency with additional information, including additional pre-clinical data, and modify the protocol design.Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the first half of 2026.The company failed to provide a new timing for the study, and said it would depend on its ability to provide the requested information and on satisfactory completion of FDA’s review.<h2 class="st-heading-2">Cassava Hits Multiple Roadblocks With Simufilam</h2>Cassava <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-drops-over-30-percent-after-drug-fails-study/ch7yzVjRbdz">discontinued</a> Simufilam’s study in mild-to-moderate Alzheimer’s disease in March after the drug did not fare better than placebo in reducing cognitive or functional decline in a late-stage study. The company discontinued its efforts to develop the drug for Alzheimer’s disease and phased out the program and then committed to evaluating the drug’s potential in TSC-related epilepsy.Tuberous Sclerosis Complex (TSC) is a rare genetic disorder causing non-cancerous tumors (hamartomas) to grow in many organs, primarily the brain, skin, kidneys, heart, lungs, and eyes. It can lead to symptoms including seizures, developmental delays, intellectual disabilities, and skin abnormalities.According to Austin-based Cassava, TSC affects nearly 50,000 people in the US and epilepsy is one of the most common neurological features of TSC, occurring in 84% of patients. Current therapies for the condition include antiepileptic drugs and mTOR inhibitors which are not fully effective, and are associated with serious adverse events, the company said in November.Cassava decided to study Simufilam in TSC-related epilepsy on the results of two sophisticated studies conducted in animals that support the drug’s potential, CEO Rick Barry said last month. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA fell from ‘bearish’ to ‘extremely bearish' territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user highlighted a buying opportunity.<stembedurl>https://www.stocktwits.com/MrStockxy/message/639701864</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 8% this year and by 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-heads-for-its-best-day-in-over-8-months-rally-isn-t-only-about-trump/cLe0GDaREst">Rocket Lab Stock Heads For Its Best Day In Over 8 Months — And The Rally Isn’t Only About Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?

FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.

Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

SAVA
Cassava Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SAVA News

SAVACassava Sciences Inc